# EDGAR Filing Document

**Accession Number:** 0002071546
**File Stem:** 0001127602-25-017211
**Filing Date:** 2025-6
**Character Count:** 5834
**Document Hash:** 88287b94349ef551141844445a20579c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001127602-25-017211.hdr.sgml**: 20250610

**ACCESSION NUMBER**: 0001127602-25-017211

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250601

**FILED AS OF DATE**: 20250610

**DATE AS OF CHANGE**: 20250610

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Mintz Mark
- **CENTRAL INDEX KEY:** 0002071546

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15943
- **FILM NUMBER:** 251037417

**MAIL ADDRESS:**
- **STREET 1:** 251 BALLARDVALE ST
- **CITY:** WILMINGTON
- **STATE:** MA
- **ZIP:** 01887
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- **CENTRAL INDEX KEY:** 0001100682
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 061397316
- **FISCAL YEAR END:** 1227

**BUSINESS ADDRESS:**
- **STREET 1:** 251 BALLARDVALE ST
- **CITY:** WILMINGTON
- **STATE:** MA
- **ZIP:** 01887
- **BUSINESS PHONE:** 781-222-6000

**MAIL ADDRESS:**
- **STREET 1:** 251 BALLARDVALE ST
- **CITY:** WILMINGTON
- **STATE:** MA
- **ZIP:** 01887

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHARLES RIVER LABORATORIES INTERNATIONAL INC
- **DATE OF NAME CHANGE:** 20000605

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHARLES RIVER LABORATORIES HOLDINGS INC
- **DATE OF NAME CHANGE:** 19991208

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Mintz Mark<br><sub>(Last) (First) (Middle)</sub><br>C/O CHARLES RIVER LABORATORIES<br>251 BALLARDVALE ST<br><sub>(Street)</sub><br>WILMINGTON, MA 01887<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-06-01 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_EVP, Chief Information Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 6350<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Options (Right to Buy) | 2022-03-01<sup>(2)</sup> | 2031-03-01 | Common Stock | 3219 | $289.61 | D |  |
| Stock Options (Right to Buy) | 2022-05-28<sup>(2)</sup> | 2031-05-28 | Common Stock | 1098 | $337.99 | D |  |
| Stock Options (Right to Buy) | 2023-05-27<sup>(3)</sup> | 2032-05-27 | Common Stock | 1437 | $244.41 | D |  |
| Stock Options (Right to Buy) | 2024-05-26<sup>(4)</sup> | 2033-05-26 | Common Stock | 1730 | $194.12 | D |  |
| Stock Options (Right to Buy) | 2025-05-31<sup>(5)</sup> | 2034-05-31 | Common Stock | 1635 | $208.44 | D |  |

---

### Footnotes:

(1) Includes (a) 133 restricted stock units (RSUs) which vest on 5/27/2026, (b) 361 restricted stock units (RSUs) which vest as follows: 180 on 5/26/2026 and 181 on 5/26/2027, (c) 540 restricted stock units (RSUs) which vest as follows: 180 on 5/31/2026, 180 on 5/31/2027 and 180 on 5/31/2028 and (d) 3,244 restricted stock units (RSUs) which vest as follows: 811 on 5/30/2026, 811 on 5/30/2027, 811 on 5/30/2028 and 811 on 5/30/2029.

(2) Stock Options fully vested.

(3) 1,077 Stock Options are vested, and the remaining Stock Options will vest on 5/27/2026.

(4) 865 Stock Options are vested, and the remaining Stock Options will vest as follows: 432 on 5/26/2026 and 433 on 5/26/2027.

(5) 408 Stock Options are vested, and the remaining Stock Options will vest as follows: 409 on 5/31/2026, 409 on 5/31/2027 and 409 on 5/31/2028.

**Signature:** /s/ Mark Mintz  
**Date:** 2025-06-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**